# 1st Gen Model Zoetis Inc. Pharmaceutical preparations

  • $63.51Last close price
    at 22-jun-2017
  • Subscribe >>
  • 78.13% successful of 32 deals

ZTS

Model's trade recommendations 2.86% Return for period

7.91% Annual return

$30.92B Market Cap

β 1.03  

ZTS

Model (following trade recommendations)

ZTS

Underlying stock

S&P 500

Index
Return for period 2.86%
1.49%
1.78%
52wk return 6.90%
32.59%
16.82%
52wk Range
45.42—63.51
2000.54—2399.63
Sortino ratio 1.17
Sharpe ratio 0.86
Norm. RMSE 0.37%
Downside risk 6.57%
Volatility 8.99%
  • 0.42 (0.67%) Div (Yield)
  • STRONG BUY Analysts consensus recommendation

Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Zoetis Inc. (ZTS) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 22, 2015.

Market data for ZTS model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 489M
P/E 31.34
Shares Outstanding 491M
% Held by Insiders 0.31%
% Held by Institutions 98.10%
EPS (last reported FY) $1.96
EPS (last reported Q) $0.53
EPS, estimated (last reported Q) $0.48
Total revenues $5 B
Net income $1 B